Abstract 231P
Background
Our research is focused on vitamin D3 active form calcitriol and its analog tacalcitol, and their interactions on the immune system, including Th17 lymphocytes, which plays a significant role in the development and progression of breast cancer. The aim was to analyze the direct effect of vitamin D compounds on its nuclear receptors in Th17 cells and changes in IL-17 production. The interaction with osteopontin (OPN) was examined as the example of indirect influence on Th17 cells population in breast cancer. Taking into account the hormonal status during disease development and stimulation of the immune system, we used mice: 6-8 weeks old as a premenopausal and 35-40 weeks old, ovariectomized, as a postmenopausal model. Our research was mainly focused on CD4+ lymphocytes isolated from spleens, looking forward to Th17 helper lymphocytes differentiation after treatment.
Methods
Animals bearing EMT6 or E0771 murine mammary gland cancer tumours were administered with calcitriol or tacalcitol from day 7 after inoculation, every three days, in the dose of 0.5 μg/kg or 1 μg/kg body weight/day, respectively. Local Ethics Committee permission No 50/2020. CD4+ cells (splenocytes) were isolated, cultured and examined for subpopulation phenotype, differentiation into Th17, gene expression profile, OPN impact on Th17 differentiation, expression of OPN receptors.
Results
Both compounds inhibited E0771 tumor growth, but tacalcitol increased metastasis in aged mice. The growth of EMT-6 tumors was stimulated in young and inhibited in aged mice after tacalcitol treatment. Metastasis was inhibited independently of the age by tacalcitol. In the E0771 premenopausal and EMT6 postmenopausal groups, tacalcitol increased the number of gene transcripts for IL17. The same tendency was observed in the E0771 postmenopausal group for the Il17 and Rorc genes. Blocking of selected CD4+ surface receptors (CD44, CD51), related to OPN functions, resulted in an increase of iTh17 cells after tacalcitol treatment. Tacalcitol in iTh17 cells induced the mRNA level for VDR, OPN, IL-21 and IL17R coding genes.
Conclusions
The Th17 induction via the OPN plays an important role, especially after tacalcitol treatment. Both compounds affect Th17 lymphocytes depending on the tumor type and age of mice.
Legal entity responsible for the study
The authors.
Funding
The National Science Center, OPUS 18 grant No. 2019/35/B/NZ5/01250.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session